Evidence map›Paper›PMID 35056856›Full record

ReviewMolecules (Basel, Switzerland)2022

Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives.

Kevin Schindler, Fabio Zobi

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Synthesis of aACS omega · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Novel Antibacterial Agents 2022.Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  14. Antimicrobial and Cytotoxic Effect ofBreast cancer (Dove Medical Press) · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Metals to combat antimicrobial resistance.Nature reviews. Chemistry · 2023
    Review
  19. Exploring the in vitro anticancer activities of Re(I) picolinic acid and its fluorinated complex derivatives on lung cancer cells: a structural study.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kevin SchindlerDepartment of Chemistry, Fribourg University, Chemin du Musée 9, 1700 Fribourg, Switzerland.ORCID 0000-0001-5487-2283
Fabio ZobiDepartment of Chemistry, Fribourg University, Chemin du Musée 9, 1700 Fribourg, Switzerland.ORCID 0000-0002-9077-7184

Funding

Swiss National Science Foundation 200021_196967
6 · The paper itself

Abstract

Organometallic compounds are increasingly recognized as promising anticancer and antibiotic drug candidates. Among the transition metal ions investigated for these purposes, rhenium occupies a special role. Its tri- and dicarbonyl complexes, in particular, attract continuous attention due to their relative ease of preparation, stability and unique photophysical and luminescent properties that allow the combination of diagnostic and therapeutic purposes, thereby permitting, e.g., molecules to be tracked within cells. In this review, we discuss the anticancer and antibiotic properties of rhenium tri- and dicarbonyl complexes described in the last seven years, mainly in terms of their structural variations and in vitro efficacy. Given the abundant literature available, the focus is initially directed on tricarbonyl complexes of rhenium. Dicarbonyl species of the metal ion, which are slowly gaining momentum, are discussed in the second part in terms of future perspective for the possible developments in the field.

Indexed as

AnimalsAnti-Bacterial AgentsAntineoplastic AgentsHumansLuminescent AgentsOrganometallic CompoundsRheniumAnti-Bacterial AgentsAntineoplastic AgentsLuminescent AgentsOrganometallic CompoundsRheniumantibioticanticancerdicarbonylheteronuclearhomonuclearrheniumtricarbonyl

Identifiers

PMID35056856
PMCPMC8777860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.